{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-285792","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.554012+00:00","generated_at":"2026-06-21T18:34:01.984573+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cue Biopharma raises $30M in PIPE financing; sells shares, pre-funded warrants, and warrants","bullets":["Gross proceeds of $30M; net proceeds ~$28.2M after fees.","Issued 7,656,966 shares, pre-funded warrants for 1,531,440 shares, and warrants for up to 9,188,406 shares at $3.265/unit.","Warrant exercise price $3.93, exercisable for 5 years; pre-funded warrants exercisable indefinitely.","Proceeds to fund CUE-101 clinical development, business development, working capital.","Closing expected Nov 16, 2022; Piper Sandler and Public Ventures as placement agents."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-285792","json":"https://secwatch.observer/filing/0001193125-22-285792.json","markdown":"https://secwatch.observer/filing/0001193125-22-285792.md","text":"https://secwatch.observer/filing/0001193125-22-285792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312522285792/0001193125-22-285792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312522285792/d420848d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:34:01.984573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55a4fdb3a811203b7a32d0769f797b5a200ffa1b","claim":"Cue Biopharma, Inc. entered into Registration Rights Agreement with accredited investors valued at not directly specified (effective 2022-11-14).","evidence_excerpt":"Also on November 14, 2022, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with the Investors, pursuant to which the Company agreed to register for resale the Shares, as well as the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants or the Warrants (the “ Warrant Shares ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312522285792/0001193125-22-285792-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"accredited investors"},{"label":"Value","value":"not directly specified"},{"label":"Effective","value":"2022-11-14"}],"fact_type":"material_agreement"},{"claim_id":"e6657e28bc4827f1ccf6f12fec5ffbe988153b2d","claim":"Cue Biopharma, Inc. entered into Securities Purchase Agreement with accredited investors valued at approximately $30.0 million aggregate gross proceeds (effective 2022-11-14).","evidence_excerpt":"On November 14, 2022, Cue Biopharma, Inc., a Delaware corporation (the “ Company ”), entered into securities purchase agreements (together, the “ Securities Purchase Agreement ”) with accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 7,656,966 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and, in lieu of Shares to certain investors, pre-funded warrants to purchase an aggregate of 1,531,440 shares of Common Stock (the “ Pre-Funded Warrants ”), and, in each case, accompanying warrants (the “ Warrants ”) to purchase an aggregate of up to 9,188,406 additional shares of Common Stock (or Pre-Funded Warrants to purchase Common Stock in lieu thereof) at a price of $3.265 per Share and accompanying Warrant (or $3.2649 per Pre-Funded Warrant and accompanying Warrant) (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312522285792/0001193125-22-285792-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"accredited investors"},{"label":"Value","value":"approximately $30.0 million aggregate gross proceeds"},{"label":"Effective","value":"2022-11-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}